

Assessment 3 References

- Grosset KA, Grosset DG. Prescribed drug and neurological complications. *J Neurol Neurosurg Psychiatry* 5(Suppl III):iii2–iii8, 2004.
- Chen, H-Y, Albertson TE, Olson KR. Treatment of drug-induced seizures. *Br J Clin Pharma* 81: 412–419, 2015.
- Falco-Walter JJ, Scheffen IE, Fisher RS. The new definition and classification of seizures and epilepsy. *Epilepsy Research* 139: 73–79, 2018.
- Chrościńska-Krawczyk M, Jargietto-Baszak M, Watek M. Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data *Pharm Reports* 63: 12-18, 2011.
- Monteiro J, Alves MG, Oliveira PF, Silva BM. Structure-Bioactivity Relationships of Methylxanthines: Trying to Make Sense of All the Promises and the Drawbacks. *Molecules* 21: 974, 2016.
- Tescarollo FC, Rombo DM, DeLiberto LK et al., Role of Adenosine in epilepsy and seizures. *J Caffeine Adenosine Res.* 10: 45-60, 2020.
- Chu N-S. Caffeine- and aminophylline-induced seizures. *Epilepsia* 22: 85-94, 1981.
- Cutrufo C, Bortot L, Giachetti A, Manzini S. Differential effects of various xanthines on pentylenetetrazole-induced seizures in rats: an EEG and behavioural study. *Eur J Pharm* 3: 1-6, 1992.
- Matovu D, Alele PE. Seizure vulnerability and anxiety responses following chronic co-administration and acute withdrawal of caffeine and ethanol in a rat model. *J Basic Clin Physiol Pharmacol.* 29: 1-10, 2018.
- Esmalili Z, Heydari A, Effect of acute caffeine administration on PTZ-induced seizure threshold in mice: Involvement of adenosine receptors and NO-cGMP signaling pathway. *Epilepsy Res.* 49: 1-8, 2019.
- Gasior M, Borowicz K, Buszewicz G et al. Anticonvulsant activity of phenobarbital and valproate against maximal electroshock in mice during chronic treatment with caffeine and caffeine discontinuation. *Epilepsia.* 37: 262-8, 1996.
- Kulkarni C, Joseph T, David J. Inhibition of anticonvulsant action of carbamazepine by aminophylline and caffeine in rats Indian. *J Exp Biol.* 27: 1048-51, 1989.
- Chrościńska-Krawczyk M, Ratnaraj N, Patsalos PN, Czuczwar SJ. Effect of caffeine on the anticonvulsant effects of oxcarbazepine, lamotrigine and tiagabine in a mouse model of generalized tonic-clonic seizures. *Pharm Reports* 61: 819-826, 2009.
- Coffey CE, Figiel GS, Weiner RD, Saunders WB. Caffeine augmentation of ECT. *Am J Psychiatry.* 147: 579-85, 1990.
- Van Koert RR, Bauer PR, Schuitema I et al. Caffeine and seizures: A systematic review and quantitative analysis. *Epilepsy & Behavior* 80: 37–47, 2018.

Iyadurai SJP, Chung SS. New-onset seizures in adults: possible association with consumption of popular energy drinks. *Epilepsy Behav.*10: 504-8, 2007.

Kaufman KR, Sachdeo RC. Caffeinated beverages and decreased seizure control. *Seizure* 12: 519–521, 2003

Vaz J, Kulkarni C, David J, Joseph T. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers. *Indian J Exp Biol* . 36: 112-4, 1998.

Dworetzky BA, Bromfield EB, Townsend MK, Kang JH. A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: Data from the Nurses' Health Study II. *Epilepsia* 51: 198–205, 2010.

Nakada T, Kwee IL, Lerner AM, Remler MP. Theophylline-induced seizures: clinical and pathophysiologic aspects. *West J Med.* 138: 371-4, 1983.

Bahls FH, Ma KK, Bird TD. Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults. *Neurology.* 41: 1309-12, 1991.

Boison D. Methylxanthines, seizures and excitotoxicity. *Handb Exp Pharmacol.* 200: 251–266, 2011.

Yoshikawa H. First-line therapy for theophylline-associated seizures. *Acta Neurol Scand.* 115(4 Suppl):57-61, 2007.